Cannabinoids have been portrayed to be able to hold therapeutic values in the treatment of chronic pain through their neuroprotective and anti inflammatory anomalies. Cannabinoids are found dwelling in the marijuana plant (cannabis sativa). Cannabinoids consist of tetrahydrocannabinol (THC) and cannabinol (CBD).
Cannabis has recently been in the research spotlight. This is due to growing interest in two of the chemicals found in the plant. THC, the chemical responsible for the “high”, and CBD, a non-psychoactive compound, are both being studied for their medicinal properties. A lot has opened up in this area as research continues into a range of areas. One such area is how cannabinoids can actually have a therapeutic value in the treatment of chronic pain.
Here is the full scientific article if you wish to download it.
In the United States, it is under review for cancer suffering, another agent Epidiolex (cannabidiol) is also under review for epilepsy in the young. Epidiolex is a synthetic cannabinoid.
Rimonabant, cannabinoid receptor 1 antagonist seems like a potentially good anti-obesity agent during clinical experiments but it also showed additional psychiatric effects. Due to which the United States FDA did not allow Rimonabant through to the next stage. Its sale was also prevented across the European Union in 2008.
Current discontinuation of clinical experiments because of severe side effects in the subjects that are taking part could be upsetting for the experimental fraternity. Despite some mishaps in clinical trials related to drugs acting on endocannabinoid system, still lots of studies are being performed to delve deeper and establish the therapeutic sites for both cannabinoid receptor agonists and antagonists.
One point of addressing this is to advance our understanding in areas that specifically investigate only cannabinoid receptors in a selective tissue. Another is to come up with agents that act specifically on cannabinoid receptors situated on the borders of the blood brain barrier. Besides this, advancement of medicines and treatments with maximum effectiveness and minimum side effects is also promoted.
Another take to be looked into for therapeutic functions of this group of agents is non-cannabinoid 1 and non-cannabinoid 2 receptor targets for cannabinoids. In order to take advantage of the therapeutic plausibility of endocannabinoid network, it is necessary to further describe the endocannabinoid network in terms of discovery of the exact cellular situation of cannabinoid receptors and their functions so medicines can be developed to utilize them.
The endocannabinoid system is a main baller in numerous physiological and pathological actions in humans. Currently, research has investigated and identified possible uses for the endocannabinoid system in:
Cannabinoid receptor 2 alteration has a plausible position in therapeutic, bone development, atherosclerosis and hepatic fibrosis. Cannabinoid receptor 1 antagonist is said to have a position as antiobesity, other cardiometabolic syndromes and drug addiction.